Dashboard
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Operating profit has grown by an annual rate 7.53% of over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
Flat results in Jun 25
3
With ROCE of 6.73%, it has a very attractive valuation with a 0.98 Enterprise value to Capital Employed
Stock DNA
Pharmaceuticals & Biotechnology
JPY 156,093 Million (Small Cap)
9.00
NA
0.00%
1.00
10.12%
0.90
Revenue and Profits:
Net Sales:
65,149 Million
(Quarterly Results - Jun 2025)
Net Profit:
2,513 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
16.42%
0%
16.42%
6 Months
13.93%
0%
13.93%
1 Year
22.7%
0%
22.7%
2 Years
48.57%
0%
48.57%
3 Years
67.55%
0%
67.55%
4 Years
27.9%
0%
27.9%
5 Years
85.93%
0%
85.93%
Towa Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
18.65%
EBIT Growth (5y)
7.53%
EBIT to Interest (avg)
46.00
Debt to EBITDA (avg)
3.98
Net Debt to Equity (avg)
1.01
Sales to Capital Employed (avg)
0.66
Tax Ratio
27.89%
Dividend Payout Ratio
18.15%
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
6.69%
ROE (avg)
9.32%
Valuation key factors
Factor
Value
P/E Ratio
9
Industry P/E
Price to Book Value
0.96
EV to EBIT
14.54
EV to EBITDA
7.80
EV to Capital Employed
0.98
EV to Sales
1.30
PEG Ratio
0.21
Dividend Yield
NA
ROCE (Latest)
6.73%
ROE (Latest)
10.56%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Shareholding Snapshot : Sep 2012
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.02%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
65,149.00
65,857.00
-1.08%
Operating Profit (PBDIT) excl Other Income
10,456.00
9,968.00
4.90%
Interest
540.00
465.00
16.13%
Exceptional Items
-1,452.00
-483.00
-200.62%
Consolidate Net Profit
2,513.00
4,362.00
-42.39%
Operating Profit Margin (Excl OI)
79.90%
70.30%
0.96%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -1.08% vs -6.36% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -42.39% vs -45.94% in Mar 2025
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
259,594.00
227,934.00
13.89%
Operating Profit (PBDIT) excl Other Income
43,342.00
35,536.00
21.97%
Interest
1,627.00
947.00
71.81%
Exceptional Items
1,209.00
5,309.00
-77.23%
Consolidate Net Profit
18,986.00
16,173.00
17.39%
Operating Profit Margin (Excl OI)
89.50%
77.40%
1.21%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 13.89% vs 9.13% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 17.39% vs 634.80% in Mar 2024
About Towa Pharmaceutical Co., Ltd. 
Towa Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






